The overwhelmingly positive feedback from the trial program suggests that Biolase's Waterlase iPlus All Tissue Laser is well-received by the dental community, which could translate into higher sales and increased market penetration. This positive news is likely to be viewed favorably by investors and could lead to a short-term uptick in BIOL's stock price.